AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cardiol Therapeutics Reports Q2 2025 Financial Results with Rising Losses Amid Ongoing Investments in Research and Development.
ByAinvest
Saturday, Aug 16, 2025 4:52 pm ET1min read
Cardiol Therapeutics has reported a net loss of $8.35 million for Q2 2025, compared to a loss of $6.59 million in the same period of 2024. The company's cash and cash equivalents decreased from $30.6 million at the end of 2024 to $18.2 million. The financial results reflect ongoing investments in research and development, with operating expenses remaining substantial. Despite promising clinical developments, the company faces substantial financial challenges.
Cardiol Therapeutics Inc. (CRDL) reported a net loss of $8.35 million for the quarter ending June 30, 2025, compared to a loss of $6.59 million in the same period of 2024. The company's cash and cash equivalents decreased from $30.6 million at the end of 2024 to $18.2 million. The financial results reflect ongoing investments in research and development, with operating expenses remaining substantial.The company's reported earnings per share (EPS) for the quarter was a loss of 10 cents, which was in line with the mean expectation of three analysts for the quarter of 12 cents per share. The reported revenue was zero, matching the analysts' expectations [2].
Despite promising clinical developments, Cardiol Therapeutics faces substantial financial challenges. The company's financial results underscore the need for continued investment in R&D to drive future growth. The company's shares have fallen by 1.5% this quarter and gained 4.7% so far this year.
Analysts have a positive outlook on the company, with the current average analyst rating on the shares being "buy." The breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." Wall Street's median 12-month price target for Cardiol Therapeutics Inc. is $9.00, about 85.1% above its last closing price of $1.34 [2].
The company's earnings date for the next quarter is estimated to be Monday, April 7th, 2025, based on last year's report dates [1].
References:
[1] https://www.marketbeat.com/stocks/NASDAQ/CRDL/earnings/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U70ZK:0-cardiol-therapeutics-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet